Xiangming Jin

Befotertinib (D-0316) versus icotinib as first-line therapy for patients with EGFR-mutated locally advanced or metastatic non-small-cell lung cancer: a multicentre, open-label, randomised phase 3 study

Shun Lü, Jianying Zhou, Hong Jian et al. · The Lancet Respiratory Medicine · 2023 · 71 citations

Medicine, Oncology, Pharmacology +14

Silencing of RAD51AP1 suppresses epithelial–mesenchymal transition and metastasis in non‐small cell lung cancer

Yuanyuan Wu, Hui-Feng Wang, Lijiao Qiao et al. · Thoracic Cancer · 2019 · 26 citations · Full text

Medicine, Molecular Biology, Oncology +17

Efficacy and Safety of Befotertinib (D-0316) in Patients With EGFR T790M-Mutated NSCLC That Had Progressed After Prior EGFR Tyrosine Kinase Inhibitor Therapy: A Phase 2, Multicenter, Single-Arm, Open-Label Study

Shun Lü, Yiping Zhang, Guojun Zhang et al. · Journal of Thoracic Oncology · 2022 · 23 citations · Full text

Medicine, Oncology, Pharmacology +11

Probabilistic life prediction for FCG degradation process of turbine disc with small sample data

Xiangming Jin, Yingdong Song, Dianyin Hu · Engineering Failure Analysis · 2020 · 15 citations

Engineering, Computational Engineering, Lifecycle Engineering +13